FOLH1 and prostate adenocarcinoma: Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, was first described as highly expressed in benign and malignant prostate epithelium (3, 4), with substantially higher PSMA expression in prostate adenocarcinoma compared to normal tissue (5, 6).